Han har sammen med en gruppe kolleger for nylig sendt et forslag til Sundhedsstyrelsen om at arbejde for at indføre neonatal screening for SMA i Danmark. Forslaget står foreløbig til at blive taget op på et møde i et udvalg i Sundhedsstyrelsen i løbet af foråret, og derefter vil det vise sig, om lægerne får opbakning til ønsket.
Roche announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review for risdiplam, an investigational survival motor neuron-2 (SMN-2) splicing modifier for SMA. Risdiplam is designed to increase and sustain SMN protein levels both throughout the central nervous system and peripheral tissues of the body. The FDA is expected to make a decision on approval by May 24, 2020.
“The FIREFISH and SUNFISH trials were designed to represent the real world spectrum of people living with SMA and include many people previously underrepresented in clinical trials,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We look forward to working closely with the FDA to explore broad access to risdiplam for all individuals in the community who might benefit.”